SPONSOR
Hellenic Cooperative Oncology Group
Total Trials
2
Recruiting
2
Phases
N/A
Hellenic Cooperative Oncology Group is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Breast Cancer, Metastatic Pancreatic Ductal Adenocarcinoma (PDAC).
Studies span multiple clinical phases, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Hellenic Cooperative Oncology Group
How many clinical trials has Hellenic Cooperative Oncology Group sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Hellenic Cooperative Oncology Group, of which 2 are actively recruiting participants. These trials cover conditions including Breast Cancer, Metastatic Pancreatic Ductal Adenocarcinoma (PDAC). Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Hellenic Cooperative Oncology Group research focus on?
Hellenic Cooperative Oncology Group clinical trials span Breast Cancer, Metastatic Pancreatic Ductal Adenocarcinoma (PDAC). Sponsor focus areas evolve as trials complete and new programs launch.
How do I participate in a Hellenic Cooperative Oncology Group clinical trial?
To participate in a Hellenic Cooperative Oncology Group trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Hellenic Cooperative Oncology Group trials with current recruitment status updated daily.
Clinical Trials by Hellenic Cooperative Oncology Group
NCT04985058
Recruiting
Real-world Data in Patients With Breast Cancer Treated With Abemaciclib
Breast Cancer
NCT07723261
Recruiting
Hellenic Evaluation of the Long-Term Safety and Efficacy of NalIriFOx as a 1st-line Therapy in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology